Skip to content
Menu

Machine translation, not reviewed.

Observatory

A trial the company describes as the first human test of partial epigenetic reprogramming

A therapy designed to return cells to a younger epigenetic state was injected into the eyes of people with optic neuropathies such as glaucoma. Company interim data: well tolerated in the first three patients, with visual-field improvement in two of them by day 56. These are data from three people, not yet peer-reviewed.

Company statement Concepts at stake: consent, risk and benefit

How to cite

Neuronet. A trial the company describes as the first human test of partial epigenetic reprogramming. Observatory, 8 October 2026. https://neuronet.pt/en/observatorio/reprogramacao-epigenetica/